TY - JOUR T1 - Modeling the impact of vaccination strategies for nursing homes in the context of increased SARS-CoV-2 community transmission and variants JF - medRxiv DO - 10.1101/2021.10.25.21265493 SP - 2021.10.25.21265493 AU - Inga Holmdahl AU - Rebecca Kahn AU - Kara Jacobs Slifka AU - Kathleen Dooling AU - Rachel B. Slayton Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/26/2021.10.25.21265493.abstract N2 - Nursing homes (NH) were among the first settings to receive COVID-19 vaccines in the United States, but staff vaccination coverage remains low at an average of 64%. Using an agent-based model, we examined the impact of community prevalence, the Delta variant, staff vaccination coverage, and boosters for residents on outbreak dynamics in nursing homes. We found that increased staff primary series coverage and high booster vaccine effectiveness (VE) in residents leads to fewer infections and that the cumulative incidence is highly dependent on community transmission. Despite high VE, high community transmission resulted in continued symptomatic infections in NHs.Competing Interest StatementRK discloses consulting fees from the Pan American Health Organization.Funding StatementRK was supported by the National Cancer Institute U01: U01 CA261277.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode will be available on github. https://github.com/rek160/NHboosters ER -